Dulaglutide (Trulicity) Dosage Calculator
Dulaglutide (brand name Trulicity) is an FDA-approved GLP-1 receptor agonist manufactured by Eli Lilly for the treatment of type 2 diabetes and reduction of major adverse cardiovascular events.
0.75mcg · Weekly
Summary: Add 0mL BAC water to your 0.75mg vial. Draw to < 0.1 units on a U-100 syringe for a 0.75mcg dose. This vial will last 0 doses.
Cycle Planner
Dulaglutide (Trulicity) Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~5 days (120 hours)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Dulaglutide (Trulicity) Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 0.75mg | Weekly |
| Moderate | 1.5mg | Weekly |
| Aggressive | 4.5mg | Weekly |
Note: FDA-approved GLP-1 receptor agonist for type 2 diabetes and cardiovascular risk reduction. Delivered via pre-filled single-use pen (Trulicity). Titrate from 0.75mg weekly; may increase every 4 weeks. Max dose 4.5mg/week.
About Dulaglutide (Trulicity)
Dulaglutide (brand name Trulicity) is an FDA-approved GLP-1 receptor agonist manufactured by Eli Lilly for the treatment of type 2 diabetes and reduction of major adverse cardiovascular events. It is a fusion protein consisting of two GLP-1 analog sequences linked to a modified human IgG4 Fc domain, giving it a molecular weight of approximately 63 kDa and a half-life of about 5 days. This allows convenient once-weekly dosing via a pre-filled, single-use pen. The REWIND trial demonstrated a 12% reduction in major cardiovascular events over a median 5.4-year follow-up, making it the first GLP-1 agonist to show cardiovascular benefit in a population with and without established cardiovascular disease.